⌘K
Loading ticker…
As of 2026-08-21, Mangoceuticals, Inc. Common Stock (MGRX) has a 3-month relative strength percentile of 39 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 38. The current market Stance is 49.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 25.1%, relative volume 0.03×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
MGRX is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $107K notional.
Held by 2 ETFs · $151K across latest filings · largest weight 0.00% (VXF).
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $107K | — |
| VXFVanguard Extended Market ETF | 0.00% | $44K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MGRX Jan avg: 1.39% median: 25.00% win: 67% σ: 45.63% n: 3 2023-03-22 → 2026-07-31 | MGRX Feb avg: 15.90% median: 36.53% win: 67% σ: 46.21% n: 3 2023-03-22 → 2026-07-31 | MGRX Mar avg: -40.39% median: -42.74% win: 0% σ: 28.66% n: 4 2023-03-22 → 2026-07-31 | MGRX Apr avg: -3.41% median: -5.42% win: 25% σ: 11.25% n: 4 2023-03-22 → 2026-07-31 | MGRX May avg: 30.85% median: 28.90% win: 100% σ: 23.95% n: 4 2023-03-22 → 2026-07-31 | MGRX Jun avg: -0.32% median: -17.20% win: 25% σ: 43.16% n: 4 2023-03-22 → 2026-07-31 | MGRX Jul avg: 12.62% median: 21.07% win: 75% σ: 37.00% n: 4 2023-03-22 → 2026-07-31 | MGRX Aug avg: 3.39% median: 9.74% win: 67% σ: 40.63% n: 3 2023-03-22 → 2026-07-31 (current) | MGRX Sep avg: -13.41% median: -7.20% win: 0% σ: 15.83% n: 3 2023-03-22 → 2026-07-31 | MGRX Oct avg: -21.33% median: -25.93% win: 0% σ: 14.57% n: 3 2023-03-22 → 2026-07-31 | MGRX Nov avg: -7.95% median: 5.49% win: 67% σ: 34.02% n: 3 2023-03-22 → 2026-07-31 | MGRX Dec avg: -33.02% median: -33.33% win: 0% σ: 29.67% n: 3 2023-03-22 → 2026-07-31 |